Top

Neurological Sciences

Published in:

01-09-2019 | Parkinson's Disease | Original Article

BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s disease—a meta-analysis

Authors: Yanying Yin, Xuening Su, Lishou Pan, Chen Li

Published in: Neurological Sciences | Issue 9/2019

Abstract

Background

Conflicting results identifying the association between Brain-derived neurotrophic factor (BDNF) polymorphism, Val66Met, and cognitive impairment in Parkinson’s disease (PD) have been reported.

Methods and results

To clarify whether Val66Met is related to cognitive impairment in PD, we carried out this meta-analysis by searching literature from PubMed, Web of Science, and Embase databases regarding this polymorphism. Six eligible studies involving 1467 PD patients were included in this meta-analysis. Our results showed statistically significant association between Val66Met and risk of cognitive impairment in PD patients in additive model (Met/Met vs. Val/Val: OR 3.82, 95%CI 1.32 to 11.08, p = 0.01) and recessive model (Met/Met vs. Val-carrier: OR 3.81, 95%CI 1.38 to 10.53, p = 0.01) except for dominant model.

Conclusions

Our meta-analysis implicates Val66Met BDNF polymorphism may be associated with Parkinson’s disease cognitive impairment, further well-designed studies with larger populations are required to validate these results owing to the limited research.

Kalia LV, Lang AE (2015) Parkinson's disease. Lancet 386:896–912CrossRefPubMed

Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130:1787–1798CrossRef

Papagno C, Trojano L (2018) Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments. Neurol Sci 39:215–223CrossRefPubMed

Jokinen P, Brück A, Aalto S, Forsback S, Parkkola R, Rinne JO (2009) Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 15:88–93CrossRefPubMed

Aleksovski D, Miljkovic D, Bravi D, Antonini A (2018) Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 39:1971–1976CrossRefPubMed

Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ (2010) Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain 133:1755–1762CrossRefPubMed

Dujardin K, Leentjens AF, Langlois C, Moonen AJ, Duits AA, Carette AS, Duhamel A (2013) The spectrum of cognitive disorders in Parkinson’s disease: a data-driven approach. Mov Disord 28:183–189CrossRefPubMed

Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9:1200–1213CrossRefPubMed

Teixeira AL, Barbosa IG, Diniz BS, Kummer A (2010) Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med 4:871–887CrossRefPubMed

10.

Guerini FR, Beghi E, Riboldazzi G, Zangaglia R, Pianezzola C, Bono G, Casali C, Di Lorenzo C, Agliardi C, Nappi G, Clerici M, Martignoni E (2009) BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol 16(11):1240–1245CrossRef

11.

Gao L, Díaz-Corrales FJ, Carrillo F, Díaz-Martín J, Caceres-Redondo MT, Carballo M, Palomino A, López-Barneo J, Mir P (2010) Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease. Acta Neurol Scand 122(1):41–45CrossRefPubMed

12.

Svetel M, Pekmezovic T, Markovic V, Novaković I, Dobričić V, Djuric G, Stefanova E, Kostić V (2013) No association between brain-derived neurotrophic factor G196A polymorphism and clinical features of Parkinson's disease. Eur Neurol 70:257–262CrossRefPubMed

13.

van der Kolk NM, Speelman AD, van Nimwegen M, Kessels RP, IntHout J, Hakobjan M, Munneke M, Bloem BR, van de Warrenburg BP (2015) BDNF polymorphism associates with decline in set shifting in Parkinson's disease. Neurobiol Aging 36:1605.e1–1605.e6CrossRef

14.

Białecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, Mak M, Deptuła-Jarosz M, Gołąb-Janowska M, Droździk M, Sławek J (2014) BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease. Neurosci Lett 561:86–90CrossRefPubMed

15.

Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH (2016) Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment. Neurosci Lett 615:88–91CrossRefPubMed

16.

Foltynie T, Lewis SG, Goldberg TE, Blackwell AD, Kolachana BS, Weinberger DR, Robbins TW, Barker RA (2005) The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease. J Neurol 252(7):833–838CrossRefPubMed

17.

Baydyuk M, Russell T, Liao GY, Zang K, An JJ, Reichardt LF, Xu B (2011) TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons. Proc Natl Acad Sci U S A 108(4):1669–1674CrossRefPubMedPubMedCentral

18.

Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230–232CrossRefPubMed

19.

McAllister AK, Katz LC, Lo DC (1999) Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22:295–318CrossRefPubMed

20.

Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257–269CrossRef

21.

Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004) Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24(18):4401–4411CrossRef

22.

Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK (2006) BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59:812–815CrossRefPubMed

23.

Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR (2004) The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24:10099–10102CrossRef

Title: BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s disease—a meta-analysis
Authors: Yanying Yin
Xuening Su
Lishou Pan
Chen Li
Publication date: 01-09-2019
Publisher: Springer International Publishing
Keyword: Parkinson's Disease
Published in: Neurological Sciences / Issue 9/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-03907-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s disease—a meta-analysis

Abstract

Background

Methods and results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2019

Correction to: Cycle ergometer training enhances plasma interleukin-10 in multiple sclerosis

The neuromodulatory effect of tDCS in patients affected by functional motor symptoms: an exploratory study

A semi-quantitative sport-specific assessment of recurrent traumatic brain injury: the TraQ questionnaire and its application in American football

Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model

Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies

Motor reaction time and accuracy in patients with multiple sclerosis: effects of an active computerized training program